Medgene Begins Field Trial on H5N1 Vaccine for Cattle

Medgene leverages its platform technology to help fight this emerging animal disease spreading across United States

Dr. Alan Young, co-founder and Chief Technology Officer for Medgene stated, “As unfortunate as the H5N1 spread is, this is exactly the kind of situation that our technology was created to address. Our goal from the very beginning of this outbreak was to be ready for our cattle customers whenever the USDA gave us the green light.”

Medgene’s H5N1 cattle vaccine study is expected to be complete in five weeks, with results then shared with the USDA.

As background, the USDA created a regulatory pathway in 2018* for animal health companies to address emerging disease challenges through vaccination. Medgene’s proprietary model of vaccine production was developed by leveraging important advances in science.

Medgene’s platform vaccines (ISPrime™) involve a carefully managed system and process that begins with field work, is heavily supported by advanced bioinformatics (Spice™) and managed by continuous surveillance of the disease environment – from farm to lab to farm.  Veterinarians are involved in every critical step.

Medgene is an animal health company headquartered in Brookings, South Dakota. Medgene’s platform vaccine technology is also licensed in swine and companion animals (rabbits), and is used in white-tailed deer.

Medgene’s platform system ensures that all the ingredients that go into its vaccines are animal origin free.

Bioinformatics is a term used to describe the practice of using software designed to understand complex, large and dynamic sets of biological data, such as that derived through monitoring disease genetics and incidence. Medgene’s Spice™ is an advanced system of biometrics that play a key role in the production of their prescription platform vaccines.

For more information on H5N1

Center for Disease Control (CDC)

https://www.cdc.gov/bird-flu/situation-summary/mammals.html